Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

被引：1

作者：

Attal, Michel ^{[1
]}

Lauwers-Cances, Valerie ^{[2
]}

Hulin, Cyrille ^{[3
]}

Facon, Thierry ^{[4
]}

Caillot, Denis ^{[5
]}

Escoffre, Martine ^{[6
]}

Arnulf, Bertrand ^{[7
]}

Macro, Margaret ^{[8
]}

Belhadj, Karim ^{[9
]}

Garderet, Laurent ^{[10
]}

Roussel, Murielle ^{[11
,12
]}

Mathiot, Claire ^{[13
]}

Avet-Loiseau, Herve ^{[1
]}

Munshi, Nikhil C. ^{[14
,15
]}

Richardson, Paul G. ^{[16
]}

Anderson, Kenneth C. ^{[17
]}

Harousseau, Jean Luc ^{[18
]}

Moreau, Philippe ^{[19
]}

机构：

[1] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[2] CHU Toulouse, Toulouse, France

[3] CHRU Hop Brabois, Nancy, France

[4] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France

[5] Hop Bocage, Dijon, France

[6] CHU Rennes, Rennes, France

[7] Hop St Louis, Paris, France

[8] CHU Caen, F-14000 Caen, France

[9] CHU Henri Mondor, F-94010 Creteil, France

[10] Hop St Antoine, F-75571 Paris, France

[11] Inst Univ Canc, Toulouse, France

[12] Univ Hosp, Dept Hematol, Toulouse, France

[13] IFM, Paris, France

[14] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[15] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[16] Harvard Univ, Sch Med, Dana Farber Canc Inst,Div Hematol Malignancy, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA

[17] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[18] HAS, Paris, France

[19] Nantes Univ Hosp, Dept Hematol, Nantes, France

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
Moreau, P
Facon, T
Attal, M
Hulin, C
Michallet, M
Maloisel, F
Sotto, JJ
Guilhot, F
Marit, G
Doyen, C
Jaubert, A
Fuzibet, JG
François, S
Benboubker, L
Monconduit, M
Voillat, L
Macro, M
Berthou, C
Dorvaux, V
Pignon, B
Rio, B
Matthes, T
Casassus, P
Caillot, D
Najman, N
Grosbois, B
Bataille, R
Harousseau, JL
BLOOD, 2002, 99 (03) : 731 - 735
[42] Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
Vescio, R
Schiller, G
Stewart, AK
Ballester, O
Noga, S
Rugo, H
Freytes, C
Stadtmauer, E
Tarantolo, S
Sahebi, F
Stiff, P
Meharchard, J
Schlossman, R
Brown, R
Tully, H
Benyunes, M
Jacobs, C
Berenson, R
DiPersio, J
Anderson, K
Berenson, J
BLOOD, 1999, 93 (06) : 1858 - 1868
[43] Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Harousseau, Jean-Luc
Attal, Michel
Avet-Loiseau, Herve
Marit, Gerald
Caillot, Denis
Mohty, Mohamad
Lenain, Pascal
Hulin, Cyrille
Facon, Thierry
Casassus, Philippe
Michallet, Mauricette
Maisonneuve, Herve
Benboubker, Lotfi
Maloisel, Frederic
Petillon, Marie-Odile
Webb, Iain
Mathiot, Claire
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4621 - 4629
[44] Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:: Preliminary results of an IFM phase II study.
Harousseau, JL
Attal, M
Leleu, X
Gressin, R
Hulin, C
Fuzibet, JG
Troncy, J
BLOOD, 2004, 104 (11) : 416A - 416A
[45] Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Dimopoulos, Meletios A.
Spicka, Ivan
Quach, Hang
Oriol, Albert
Hajek, Roman
Garg, Mamta
Beksac, Meral
Bringhen, Sara
Katodritou, Eirini
Chng, Wee-Joo
Leleu, Xavier
Iida, Shinsuke
Mateos, Maria-Victoria
Morgan, Gareth
Vorog, Alexander
Labotka, Richard
Wang, Bingxia
Palumbo, Antonio
Lonial, Sagar
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 4030 - 4041
[46] UPFRONT SINGLE VERSUS DOUBLE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTER, PHASE III STUDY OF THE EUROPEAN MYELOMA NETWORK (EMN02/HO95 MM TRIAL)
Pantani, L.
Petrucci, M. T.
Patriarca, F.
Galli, M.
de Rosa, L.
Testoni, N.
Tosi, P.
Terragna, C.
Zamagni, E.
Nozza, A.
Baraldi, A.
Narni, F.
De Sabbata, G.
Troia, R.
Pescosta, N.
Canepa, L.
Ronconi, S.
Musto, P.
Musolino, C.
Boccadoro, M.
Sonneveld, P.
Cavo, M.
HAEMATOLOGICA, 2017, 102 : 25 - 26
[47] VELCADE/Dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): An interim analysis of the IFM 2005-01 randomized multicenter phase III trial.
Harousseau, Jean-Luc
Marit, Gerald
Caillot, Denis
Casassus, Philippe
Facon, Thierry
Mohty, Mohamad
Maloisel, Frederic
Maisonneuve, Herve
Chaleteix, Carine
Benboubker, Lofti
Esseltine, Dixie-Lee
Attal, Michel
BLOOD, 2006, 108 (11) : 21A - 21A
[48] Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
Moreau, Philippe
Attal, Michel
Caillot, Denis
Macro, Margaret
Karlin, Lionel
Garderet, Laurent
Facon, Thierry
Benboubker, Lotfi
Escoffre-Barbe, Martine
Stoppa, Anne-Marie
Laribi, Kamel
Hulin, Cyrille
Perrot, Aurore
Marit, Gerald
Eveillard, Jean-Richard
Caillon, Florence
Bodet-Milin, Caroline
Pegourie, Brigitte
Dorvaux, Veronique
Chaleteix, Carine
Anderson, Kenneth
Richardson, Paul
Munshi, Nikhil C.
Avet-Loiseau, Herve
Gaultier, Aurelie
Nguyen, Jean-Michel
Dupas, Benoit
Frampas, Eric
Kraeber-Bodere, Francoise
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) : 2911 - +
[49] Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
Cavo, Michele
Petrucci, Maria Teresa
Di Raimondo, Francesco
Zamagni, Elena
Gamberi, Barbara
Crippa, Claudia
Marzocchi, Giulia
Grasso, Mariella
Ballanti, Stelvio
Vincelli, Donatella Iolanda
Tacchetti, Paola
Offidani, Massimo
Semenzato, Gianpietro
Liberati, Anna Marina
Pascarella, Anna
Benevolo, Giulia
Troia, Rossella
Palmas, Angelo D.
Cantore, Nicola
Rizzi, Rita
Morabito, Fortunato
Boccadoro, Mario
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[50] A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial
Stewart, Keith
Trudel, Suzanne
Bahlis, Nizar J.
White, Darrell J.
Sabry, Waleed
Belch, Andrew
Reiman, Tony
Roy, Jean
Shustik, Chaim
Kovacs, Michael J.
Sussman, Jonathan
Meyer, Ralph M.
Harnett, Erica L.
Oana, Danila
Chapman, Judy A.
Shepherd, Lois
BLOOD, 2010, 116 (21) : 23 - 23

← 1 2 3 4 5 →